Late complications of the treatment of patients with germ cell tumors-Reference-Cited by-同舟云学术

Late complications of the treatment of patients with germ cell tumors

Published:2020-07-22 Issue:2 Volume:16 Page:152-161
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Danielyan D. G.¹,Salimova A. A.¹,Bulanov A. A.²,Fedyanin M. Yu.³^ORCID,Tryakin A. A.⁴^ORCID

Affiliation:

1. I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

3. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Peoples’ Friendship University of Russia

4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Clinic “K + 31 City”; Bashkir State Medical University, Ministry of Health of Russia; 47Zaki Validi St., Ufa 450008, Republic of Bashkortostan; .S. Loginov Moscow Clinical Scientific Center, Moscow Healthcare Department

Abstract

Germ cell tumors are one of the highly sensitive to chemotherapy, and about 80 % of patients can be cured even having metastases. Apartfrom acute toxicity, chemotherapy is characterized by late complications that occur many years later and not only negatively affect the quality of life, but in some cases are life-threatening. The review summarizes the results of studies on the late complications’ occurrence and prevention when treating patients with germ cell tumors.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference82 articles.

1. Meinardi M.T., Gietema J.A., van der Graaf W.T. et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32. DOI: 10.1200/JC0.2000.18.8.1725.

2. Nuver J., Smit A.J., Sleijfer D.T. et al. Microalbuminuria, decreased fibrinolysis and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40(5):701-6. DOI: 10.1016/j.ejca.2003.12.012.

3. Thogersen A.M., Jansson J.H., Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for fibrinolytic system as an independent primary risk factor. Circulation 1998;98(21):2241—7. DOI: 10.1161/01.cir.98.21.2241.

4. Juhan-Vague I., Pyke S.D., Alessi M.C. et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation Circulation 1996;94(9):2057—63. DOI: 10.1161/01.cir.94.9.2057.

5. Gietema, J.A., Meinardi, M.T., Messerschmidt J. et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355(9209):1075—6. DOI: 10.1016/s0140-6736(00)02044-4.